Growth engines stall, shifting focus to a pending deal
- Management cut guidance in Q2 2026 due to sudden slowdowns in key heart products.
- The WATCHMAN device is seeing fewer referrals as new clinical data shifts doctor behavior.
- The FARAPULSE ablation system is facing heavier competition than management expected in the U.S. market.
- Boston Scientific expects limited earnings growth in 2027, pushing a return to fast growth to 2028.
- The pending $14.5 billion Penumbra acquisition is now critical to bridge the near term gap.
Stalled engines and a critical deal
Boston Scientific recently faced a sharp shift in its story. The twin engines of recent growth, WATCHMAN and Electrophysiology, abruptly slowed in the U.S. market during the second quarter of 2026. This forced management to reduce guidance and warn of limited earnings growth in 2027.
The bull case relies on a strong base business that makes up 75 percent of revenue and grows steadily at about 6 percent. Bulls also look forward to the pending $14.5 billion Penumbra acquisition, expected to close in the second half of 2026. This deal would make Boston Scientific a leader in removing blood clots and help offset weakness elsewhere. A $500 million restructuring program is also underway to protect profit margins.
The bear case argues that the company underestimated the speed of market changes. WATCHMAN referrals are pausing due to new clinical data. In Electrophysiology, competitors are taking market share faster than expected as new technologies mature. Boston Scientific must now survive a difficult 2027 while waiting for new products, like the FARAWAVE Ultra, to launch and restore growth in 2028.
Less invasive tools, sold worldwide
Boston Scientific develops, makes, and sells medical devices for procedures that often replace more invasive surgery. Hospitals and doctors use its tools in heart, blood vessel, digestive, bladder, nerve, pain, and cancer procedures.
The company makes money by selling devices and related systems across two segments, Cardiovascular and MedSurg. Its edge comes from patents, clinical data, trained sales teams, long doctor relationships, and knowing how to get devices cleared by regulators.
Growth comes from two paths. First, the company improves and launches new products. Second, it buys companies in nearby markets, such as Axonics, Silk Road Medical, and the proposed Penumbra deal. That strategy can work well, but it depends on paying the right price, closing deals, and fitting new products into the sales machine.
Where it can break: regulators can delay approvals, insurers can reduce payment, hospitals can push back on price, rivals can copy or beat products, and acquired businesses can disappoint. For Boston Scientific, the current test is whether it can fix its core cardiology issues while pushing a massive deal across the finish line.
Devices that drive the story
FARAPULSE
FARAPULSE is a pulsed field ablation system for Electrophysiology. It led recent growth, but the Q2 2026 filing flagged intense competition causing market share loss.
WATCHMAN
WATCHMAN closes the left atrial appendage in certain heart patients to reduce stroke risk. Procedure growth slowed sharply in 2026 due to changing referral patterns.
Interventional Cardiology
This group includes coronary stents, imaging catheters, and AGENT drug-coated balloons. It provides a steady base of heart procedures beyond ablation and WATCHMAN.
Urology and Axonics
Urology includes kidney stone, prostate, and incontinence products. The Axonics acquisition added sacral neuromodulation systems and helped drive recent segment growth.
Endoscopy
Endoscopy sells tools for digestive system procedures, including EXALT single-use scopes, Resolution 360 clips, and AXIOS stents. It is a steady part of MedSurg.
Penumbra thrombectomy
Penumbra would add clot removal products such as Lightning Bolt and Lightning Flash. The pending deal faces an FTC Second Request but is critical for 2027 growth.
Cardiovascular leads the mix
Segment mix is based on full-year 2025 net sales. Cardiovascular was 66 percent of sales, exposing the company heavily to recent heart and vascular procedure shifts.
What could break the thesis
WATCHMAN referrals stall
High impact · High oddsWATCHMAN has been one of the most important heart franchises for the company. Q2 2026 results showed a sharp drop in procedures as clinical data caused doctors to delay referrals. If education and marketing fail to reverse this trend, a major profit engine breaks.
Electrophysiology share loss accelerates
High impact · High oddsFARAPULSE drove massive growth recently, but the market transitioned faster than expected. With new technology now holding 80 percent of the market, competitors are taking share from Boston Scientific. The company needs to hold ground until FARAWAVE Ultra launches in late 2027.
FTC blocks or delays Penumbra
High impact · Medium oddsThe Penumbra deal is valued at about $14.5 billion and is critical to bridging the expected growth gap in 2027. The FTC Second Request raises the chance that closing takes longer, needs remedies, or fails entirely. A blocked deal would leave the company heavily exposed to its stalling heart franchises.
Pricing and reimbursement pressure
Medium impact · High oddsHospitals, insurers, and government health systems constantly push medical device prices lower. If reimbursement changes make procedures less profitable for doctors or hospitals, demand can slow. This common risk matters more when core product growth is already under pressure.
In one breath
What does Boston Scientific actually sell?
It sells medical devices used in less invasive procedures. Its biggest areas include heart devices, blood vessel tools, digestive procedure tools, urology devices, and neuromodulation systems for pain and movement disorders.
Why is the Penumbra deal so important right now?
Penumbra would give the company a larger position in removing blood clots. Because core heart products like WATCHMAN have slowed down, management is relying heavily on Penumbra to drive earnings growth in 2027.
What happened to FARAPULSE?
FARAPULSE was a major growth driver, but the market adopted the new technology so fast that competitors caught up. Boston Scientific lost more market share than management anticipated and is now waiting for next-generation products in 2027.
